MARKETS PERPS LIVE82 SOCIAL

Cash

Portfolio

Search

Trending Elections Politics Sports Culture Crypto Commodities Climate Economics Mentions

Finance

Portfolio

Search

Product

Perpetual Futures Markets Incentive program Institutions API & developers

Company

About Kalshi Research Blog Careers Policy Center Brand Kit

Help

Help Center FAQ Fee schedule Trading hours Regulatory

© 2026 Kalshi Inc. · All rights reserved

Privacy Data Terms of Service Trading Prohibitions FAQ for Finance Professionals

Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Trending Elections Politics Sports Culture Crypto Commodities Climate Economics Mentions

Finance

Product launches

Foreign Exchange

Biotech

Biotech Odds & Predictions 2026

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.62x

No

2.05x

$470 vol1 market

FDA decision: Iberdomide by Celgene (this year)

Yes

1.34x

No

2.98x

$614 vol1 market

FDA decision: Zidesamtinib by Nuvalent (this year)

Yes

1.25x

No

3.52x

$100 vol1 market

FDA decision: Venglustat by Sanofi (this year)

Yes

1.15x

No

4.51x

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.31x

No

3.08x

$131 vol1 market

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes

1.10x

No

6.29x

$114 vol1 market

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes

1.22x

No

3.80x

$30 vol1 market

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes

1.44x

No

2.59x

$90 vol1 market

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes

1.22x

No

3.80x

$47 vol1 market

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes

1.05x

No

9.41x

$11 vol1 market

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes

1.29x

No

3.18x

$64 vol1 market

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.06x

No

8.56x

$18 vol1 market

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.23x

No

3.80x

$458 vol1 market